Co-Diagnostics, Inc. (NASDAQ:CODX – Get Free Report) was the recipient of a large decrease in short interest in the month of July. As of July 31st, there was short interest totalling 309,900 shares, a decrease of 12.3% from the July 15th total of 353,200 shares. Based on an average trading volume of 130,300 shares, the days-to-cover ratio is currently 2.4 days.
Wall Street Analysts Forecast Growth
Separately, HC Wainwright lowered their target price on shares of Co-Diagnostics from $2.00 to $1.50 and set a “neutral” rating on the stock in a report on Monday, August 12th.
Get Our Latest Stock Analysis on CODX
Institutional Inflows and Outflows
Co-Diagnostics Stock Up 26.0 %
Shares of CODX traded up $0.36 during mid-day trading on Monday, hitting $1.72. 2,010,715 shares of the company’s stock were exchanged, compared to its average volume of 107,305. Co-Diagnostics has a 52 week low of $0.98 and a 52 week high of $1.94. The stock’s 50-day simple moving average is $1.29 and its 200-day simple moving average is $1.20. The firm has a market cap of $53.80 million, a price-to-earnings ratio of -1.30 and a beta of -0.82.
About Co-Diagnostics
Co-Diagnostics, Inc, a molecular diagnostics company, develops, manufactures, and sells reagents used for diagnostic tests that function through the detection and/or analysis of nucleic acid molecules in the United States and internationally. The company offers Co-Dx PCR platform, a polymerase chain reaction (PCR) testing to patients in point-of-care and at-home setting.
See Also
- Five stocks we like better than Co-Diagnostics
- Consumer Discretionary Stocks Explained
- Moderna Dips on Q2 Earnings But Can It Rip on a Short Squeeze?
- Dividend Screener: How to Evaluate Dividend Stocks Before Buying
- 2 Option Strategies to Maximize Profits in a Bear Market
- What Are Dividend Champions? How to Invest in the Champions
- Lululemon Stock Gears Up for a Massive Comeback Rally
Receive News & Ratings for Co-Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Co-Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.